Suvorexant
BELSOMRA
Orexin Receptor Antagonist
NADAC/unit
$15.2156
No Shortage
Tier 1: 34.0%
PA Req: 47.4%
BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
vs. brand BELSOMRA: Generic saves up to -52% per unit
Market Intelligence
2025-08-20 Class II Recall: Merck & Co. Inc
Generic Manufacturers
MERCK SHARP AND DOHME CORP
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.